ArticleJournal of cellular and molecular medicine2026
Increased CD44 Expression in Endothelial Cells Induced by Advanced Glycation End Products Leads to Insufficient Maturation of Angiogenesis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pathological angiogenesis occurs in various diseases, including tumours, diabetes and wound healing. The endothelial cells lining these aberrant neovessels exhibit abnormal morphology, with loosely attached or absent pericytes and the basement membrane (BM) is often disrupted. Advanced glycation end products (AGEs) promote pathological angiogenesis in diabetic vascular complications, but whether the vascular BM structure is altered and the underlying molecular mechanisms remain unclear. By analysing single-cell RNA sequencing data (GSE204880) from the oxygen-induced retinopathy mouse model, this study found heterogeneous expression of type IV collagen (Col-IV) and laminin in endothelial cells, with enrichment of the AGE-RAGE pathway and BM-related pathways. Experimental results demonstrated that AGEs induce abnormal distribution of Col-IV in vascular BM, along with increased Col-IV levels in mouse serum and endothelial-pericyte co-culture supernatants, suggesting excessive BM degradation. Additionally, AGEs upregulated CD44 and matrix metalloproteinases 9 (MMP9) protein levels in retinal tissues and endothelial cells. Knockout/knockdown of CD44 or inhibition of MMP9, can both significantly alleviate BM structural disruption and abnormal angiogenesis. The down-regulation of CD44 expression or application of γ-secretase inhibitor DAPT attenuated AGEs-promoted MMP9 expression and secretion. Moreover, AGEs facilitated β-catenin nuclear translocation and its interaction with TCF4. When this interaction was blocked by LF3, AGEs-induced CD44 upregulation was reduced, and pathological angiogenesis and BM abnormalities were partially restored. These findings suggest that AGEs upregulate endothelial CD44 expression via β-catenin/TCF4 signalling pathway, which in turn promotes MMP9-mediated excessive degradation of BM components, leading to structural disorganisation and impaired vascular maturation in pathological angiogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.